Development and evaluation of a novel radioiodinated vesamicol analog as a sigma receptor imaging agent

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-10

  Ogawa, Kazuma ^a   Kanbara, Hiroya ^a   Shiba, Kazuhiro ^a   Kitamura, Yoji ^a   Kozaka, Takashi ^a   Kiwada, Tatsuto ^a   Odani, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cancer; Imaging; Sigma receptor

Indexed keywords

2 [4 (4 IODOPHENYL)PIPERIDINO]CYCLOHEXANOL I 131; 4 [1 (2 HYDROXYCYCLOHEXYL)PIPERIDINE 4 YL] 2 IODOPHENOL I 125; CUTAMESINE; HALOPERIDOL; RADIOPHARMACEUTICAL AGENT; SIGMA OPIATE RECEPTOR; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG; VESAMICOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN DU 145; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; HYDROPHILICITY; ISOTOPE LABELING; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOIODINATION; RECEPTOR BLOCKING;

EID: 84874315892     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-54     Document Type: Article

References (33)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE: The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976, 197:517-532.
2. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP: A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992, 13:85-86.
3. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H: Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci USA 1996, 93:8072-8077.
4. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 1996, 229:553-558.
5. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS, Hawkins WG, Wheeler KT, Mach RH: Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011, 2:380.
6. Su TP: Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol 1993, 7:187-203.
7. Luedtke RR, Perez E, Yang SH, Liu R, Vangveravong S, Tu Z, Mach RH, Simpkins JW: Neuroprotective effects of high affinity sigma 1 receptor selective compounds. Brain Res 2012, 1441:17-26.
8. Maurice T, Su TP: The pharmacology of sigma-1 receptors. Pharmacol Ther 2009, 124:195-206.
9. Wang HH, Chien JW, Chou YC, Liao JF, Chen CF: Anti-amnesic effect of dimemorfan in mice. Br J Pharmacol 2003, 138:941-949.
10. Utech T, Kohler J, Buschmann H, Holenz J, Vela JM, Wunsch B: Synthesis and pharmacological evaluation of a potent and selective sigma1 receptor antagonist with high antiallodynic activity. Arch Pharm (Weinheim) 2011, 344:415-421.
11. Sabino V, Cottone P, Blasio A, Iyer MR, Steardo L, Rice KC, Conti B, Koob GF, Zorrilla EP: Activation of sigma-receptors induces binge-like drinking in Sardinian alcohol-preferring rats. Neuropsychopharmacology 2011, 36:1207-1218.
12. Vilner BJ, John CS, Bowen WD: Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55:408-413.
13. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, Coscia CJ: Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1991, 51:6558-6562.
14. Aydar E, Palmer CP, Djamgoz MB: Sigma receptors and cancer: possible involvement of ion channels. Cancer Res 2004, 64:5029-5035.
15. Mach RH, Smith CR, Al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT: Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997, 57:156-161.
16. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH: Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000, 82:1223-1232.
17. Hirata M, Mori T, Umeda T, Abe T, Yamamoto T, Ohmomo Y: Evaluation of radioiodinated 1-[2-(3, 4-Dimethoxyphenyl)ethyl]-4-(2-iodophenylpropyl) piperazine as a tumor diagnostic agent with functional sigma receptor imaging by single photon emission computed tomography. Biol Pharm Bull 2008, 31:879-883.
18. Megalizzi V, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Neve N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, Kondo Y, Kiss R, Lefranc F: 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 2007, 9:358-369.
19. Spruce BA, Campbell LA, McTavish N, Cooper MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K, McLean D, Leslie NR, Safrany ST, Ferguson MJ, Peters JA, Prescott AR, Box G, Hayes A, Nutley B, Raynaud F, Downes CP, Lambert JJ, Thompson AM, Eccles S: Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004, 64:4875-4886.
20. 18F-FDG uptake in rat gliomas after in vivo treatment with doxorubicin. J Nucl Med 2007, 48:1320-1326.
21. Shiba K, Yano T, Sato W, Mori H, Tonami N: Characterization of radioiodinated (-)-ortho-iodovesamicol binding in rat brain preparations. Life Sci 2002, 71:1591-1598.
22. Shiba K, Ogawa K, Mori H: In vitro characterization of radioiodinated (+)-2-[4-(4-iodophenyl) piperidino]cyclohexanol [(+)-pIV] as a sigma-1 receptor ligand. Bioorg Med Chem 2005, 13:1095-1099.
23. Ogawa K, Shiba K, Akhter N, Yoshimoto M, Washiyama K, Kinuya S, Kawai K, Mori H: Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy. Cancer Sci 2009, 100:2188-2192.
24. Shiba K, Mori H, Matsuda H, Tsuji S, Tonami N, Hisada K: In vivo characterization of radioiodinated 2-(4-phenylpiperidino)cyclohexanol (vesamicol) analogs: potential radioligand for mapping presynaptic cholinergic neurons. Nucl Med Biol 1995, 22:823-828.
25. Rogers GA, Parsons SM, Anderson DC, Nilsson LM, Bahr BA, Kornreich WD, Kaufman R, Jacobs RS, Kirtman B: Synthesis, in vitro acetylcholine-storageblocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol). J Med Chem 1989, 32:1217-1230.
26. Shiba K, Mori H, Matsuda H, Tsuji S, Kuji I, Sumiya H, Kinuya K, Tonami N, Hisada K, Sumiyosi T: Synthesis of radioiodinated analogs of 2-(4-phenylpiperidino)cyclohexanol (vesamicol) as vesamicol-like agent. Nucl Med Biol 1995, 22:205-210.
27. Wilbur DS, Hadley SW, Grant LM, Hylarides MD: Radioiodinated iodobenzoyl conjugates of a monoclonal antibody Fab fragment. In vivo comparisons with chloramine-T-labeled Fab. Bioconjug Chem 1991, 2:111-116.
28. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S: Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol 1996, 306:271-279.
29. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD: Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994, 268:9-18.
30. Ogawa K, Mukai T: Targeted imaging and therapy for bone metastases: control of pharmacokinetics of bone-targeted radiopharmaceuticals. J Drug Deliv Sci Technol 2009, 19:171-176.
31. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD: Targeting sigma receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 1999, 59:4578-4583.
32. Hashimoto K, Ishiwata K: Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006, 12:3857-3876.
33. Li ZJ, Ren HY, Cui MC, Deuther-Conrad W, Tang RK, Steinbach J, Brust P, Liu BL, Jia HM: Synthesis and biological evaluation of novel 4-benzylpiperazine ligands for sigma-1 receptor imaging. Bioorg Med Chem 2011, 19:2911-2917.